The partnership will allow Cobra Biologics to advance both KAHR-101 and KAHR -102 for future pre-clinical and clinical testing using Cobra Biologic’s MaxXpress service which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team, to enable rapid clone selection and production. Cobra Biologics will also be carrying out the process development and scale up for the GMP production of both KAHR-101 and KAHR-102.
Peter Coleman, CEO at Cobra Biologics, said: “I am delighted to extend our partnership with KAHR which has been strengthened over a number of years due to the excellent working relationship between both technical teams and we look forward to its continuation.”
Dr Noam Shani, CEO of KAHR Medical, said: “It has been a pleasure working with Cobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of both KAHR-101 and KAHR-102.”